Get the tools used by (smart)2 investors.
SP500 0.7%DOW 0.0%FTSE 100 0.4%NIKKEI 0.5%OIL 0.8%GOLD -1.1%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Upside (Analyst Target) for Arcutis Biotherapeutics Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

ARQT: Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream fo...

14.61 USD
Price
– USD
Fair Value
–
Upside
6.99 - 17.75
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Arcutis Biotherapeutics Inc's Upside (Analyst Target):

Dec 2016Dec 2018Dec 2020Dec 2022Dec 202450.0%100.0%150.0%200.0%250.0%
Performance Summary
  • Arcutis Biotherapeutics Inc's latest twelve months upside (analyst target) is 36.9%
  • Arcutis Biotherapeutics Inc's upside (analyst target) for fiscal years ending December 2020 to 2024 averaged 142.1%.
  • Arcutis Biotherapeutics Inc's operated at median upside (analyst target) of 160.4% from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Arcutis Biotherapeutics Inc's upside (analyst target) peaked in December 2022 at 241.2%.
  • Arcutis Biotherapeutics Inc's upside (analyst target) hit its 5-year low in December 2024 of 36.9%.
  • Arcutis Biotherapeutics Inc's upside (analyst target) decreased in 2023 (194.1%, -19.5%) and 2024 (36.9%, -81.0%) and increased in 2021 (160.4%, +106.3%) and 2022 (241.2%, +50.4%).

Benchmarks

Metric Usage: Upside (Analyst Target)

Hide this widget
analyst_target_upside
Slug
number
Datatype
text
Format
current
Default Period
FY, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Upside (Analyst Target) in the predictions category include:

  • Analyst Price Target Count - The number of analyst price targets tracked for a stock. Price targets represent what analysts believe a stock will be worth within the next 12 to 18 months.
  • Fair Value - The Fair Value is an estimation determined through various valuation models, including discounted cash flow analysis, peer valuation multiples models, and dividend discount models.
  • Predicted Price / Fwd Sales Ratio (FY+2) - Our estimate of the fair value Price / Fwd Sales Ratio (FY+2) for a company.
  • Analyst Price Target Low - The lowest analyst price target for a stock. Price targets represent what analysts believe a stock will be worth within the next 12 to 18 months.
View Full List

Search for metric or datapoint

Upside (Analyst Target)

The percentage increase (if positive) or decrease (if negative) that professional analysts expect over the current stock price.

Definition of Upside (Analyst Target)

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
0.0%700.0%1,400.0%2,675.9%100300500

The chart above depicts the distribution of upside (analyst target) for companies operating in the Healthcare sector in the Developed economic region. Over 1,410 companies were considered in this analysis, and 1,363 had meaningful values. The average upside (analyst target) of companies in the sector is 234.0% with a standard deviation of 344.1%.

Arcutis Biotherapeutics Inc's Upside (Analyst Target) of 36.9% ranks in the 26.0% percentile for the sector. The following table provides additional summary stats:

Upside (Analyst Target) In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents1,419
Included Constituents1,363
Min-3.5%
Max2,658.6%
Median96.9%
Mean234.0%
Standard Deviation344.1%

You can find companies with similar upside (analyst target) using this stock screener.

All rights reserved. Terms Of Use